http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
한국형 공개SW 표준 플랫폼 BOOYO 기반의 WAS구축 및 SPECjAppServer2004 벤치마킹 연구
김두현,김리라,정성인 건국대학교 산업기술연구원 2005 건국기술연구논문지 Vol.30 No.-
We efficiently loaded Tomcat, JBoss, PostreSQL and Apache which are the core of publicly published open Source based WAS middleware on Booyo in Korea Open Source Standard Platform. This paper compare performance of Booyo with performance of foreign products using SPECjAppsserver2004 banchmark. In benchmark if Booyo increases a load, JOPS for a performance measurement unit falls a small number. Therefore. this paper describes a result and building a research WAS.
Bortezomib과 Dexamthasone으로 치료한 골수외 형질세포종 4예
백종현,이은영,장리라,손창배,신은경,서정아,이지숙,이호섭,이상민,신성훈,김양수 고신대학교의과대학 2007 고신대학교 의과대학 학술지 Vol.22 No.2
Despite the use of aggressive local and systemic treatment including autologous stem cell transplantation in multiple myeloma, extramedullary recurrences are common and the prognosis of these patients is poor. Many novel drugs such as thalidomide, lenalidomide and bortezomib improve the response of treatment of multiple myeloma, but some reports failed to describe thalidomide has effect in extramedullary plasmacytoma. Recent data report on the successful treatment plasmacytomas with bortezomib in patients with advanced multiple myeloma. We treated 4 relapsed or refractory extramedullary plasmacytomas with bortezomib at our institution. We recognized all these extramedullary plasmacytomas decreased and showed more than partial response. This report lends support to the efficacy of bortezomib in the treatment of plasmacytoma and describes the safe use of bortezomib. Responses may, however, be of short duration. Therefore, despite our limited experience, we propose that bortezomib may be considered a therapeutic option for such patients who have risk of radiation therapy